Nephros Statistics
Total Valuation
Nephros has a market cap or net worth of $30.30 million. The enterprise value is $26.53 million.
| Market Cap | 30.30M |
| Enterprise Value | 26.53M |
Important Dates
The last earnings date was Thursday, November 5, 2026, after market close.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nephros has 10.86 million shares outstanding. The number of shares has increased by 2.84% in one year.
| Current Share Class | 10.86M |
| Shares Outstanding | 10.86M |
| Shares Change (YoY) | +2.84% |
| Shares Change (QoQ) | +0.82% |
| Owned by Insiders (%) | 17.78% |
| Owned by Institutions (%) | 17.87% |
| Float | 8.93M |
Valuation Ratios
The trailing PE ratio is 15.70 and the forward PE ratio is 12.31.
| PE Ratio | 15.70 |
| Forward PE | 12.31 |
| PS Ratio | 1.40 |
| Forward PS | 1.27 |
| PB Ratio | 2.42 |
| P/TBV Ratio | 2.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 13.88 |
| EV / Sales | 1.23 |
| EV / EBITDA | 13.59 |
| EV / EBIT | 14.50 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.50, with a Debt / Equity ratio of 0.06.
| Current Ratio | 5.50 |
| Quick Ratio | 3.37 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.32 |
| Debt / FCF | n/a |
| Interest Coverage | 1,829.00 |
Financial Efficiency
Return on equity (ROE) is 16.95% and return on invested capital (ROIC) is 21.48%.
| Return on Equity (ROE) | 16.95% |
| Return on Assets (ROA) | 8.01% |
| Return on Invested Capital (ROIC) | 21.48% |
| Return on Capital Employed (ROCE) | 14.18% |
| Weighted Average Cost of Capital (WACC) | 13.56% |
| Revenue Per Employee | $599,444 |
| Profits Per Employee | $53,083 |
| Employee Count | 36 |
| Asset Turnover | 1.51 |
| Inventory Turnover | 2.21 |
Taxes
In the past 12 months, Nephros has paid $13,000 in taxes.
| Income Tax | 13,000 |
| Effective Tax Rate | 0.68% |
Stock Price Statistics
The stock price has decreased by -50.97% in the last 52 weeks. The beta is 1.75, so Nephros's price volatility has been higher than the market average.
| Beta (5Y) | 1.75 |
| 52-Week Price Change | -50.97% |
| 50-Day Moving Average | 3.79 |
| 200-Day Moving Average | 3.63 |
| Relative Strength Index (RSI) | 29.17 |
| Average Volume (20 Days) | 49,667 |
Short Selling Information
The latest short interest is 15,442, so 0.14% of the outstanding shares have been sold short.
| Short Interest | 15,442 |
| Short Previous Month | 25,302 |
| Short % of Shares Out | 0.14% |
| Short % of Float | 0.17% |
| Short Ratio (days to cover) | 0.43 |
Income Statement
In the last 12 months, Nephros had revenue of $21.58 million and earned $1.91 million in profits. Earnings per share was $0.18.
| Revenue | 21.58M |
| Gross Profit | 13.07M |
| Operating Income | 1.83M |
| Pretax Income | 1.92M |
| Net Income | 1.91M |
| EBITDA | 1.95M |
| EBIT | 1.83M |
| Earnings Per Share (EPS) | $0.18 |
Balance Sheet
The company has $4.55 million in cash and $774,000 in debt, with a net cash position of $3.77 million or $0.35 per share.
| Cash & Cash Equivalents | 4.55M |
| Total Debt | 774,000 |
| Net Cash | 3.77M |
| Net Cash Per Share | $0.35 |
| Equity (Book Value) | 12.55M |
| Book Value Per Share | 1.15 |
| Working Capital | 10.85M |
Cash Flow
| Operating Cash Flow | -910,000 |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 123,000 |
| Net Borrowing | -5,000 |
| Free Cash Flow | -910,000 |
| FCF Per Share | -$0.08 |
Margins
Gross margin is 60.55%, with operating and profit margins of 8.48% and 8.86%.
| Gross Margin | 60.55% |
| Operating Margin | 8.48% |
| Pretax Margin | 8.92% |
| Profit Margin | 8.86% |
| EBITDA Margin | 9.05% |
| EBIT Margin | 8.48% |
| FCF Margin | n/a |
Dividends & Yields
Nephros does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.84% |
| Shareholder Yield | n/a |
| Earnings Yield | 6.37% |
| FCF Yield | -3.00% |
Analyst Forecast
The average price target for Nephros is $6.25, which is 124.01% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.25 |
| Price Target Difference | 124.01% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 15.68% |
| EPS Growth Forecast (3Y) | 42.75% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on July 10, 2019. It was a reverse split with a ratio of 1:9.
| Last Split Date | Jul 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:9 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |